The Danish drugmaker Novo Nordisk is enlisting two Flagship biotechs to develop drugs to treat obesity and the condition known as MASH.
Comments
(._.)
There's nothing here…
The Danish drugmaker Novo Nordisk is enlisting two Flagship biotechs to develop drugs to treat obesity and the condition known as MASH.